ArticlePharmaceutical research2026
Whole-Body Pharmacokinetics of Lipid, mRNA and Translated Protein Following Intravenous Administration of Spike Protein Expressing mRNA-LNP in Mice.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimLipid nanoparticle (LNP)-encapsulated mRNAs (mRNA-LNPs) are being explored for various prophylactic and therapeutic applications. However, the relationship between the pharmacokinetics (PK) of lipid, mRNA, and expressed protein across tissues remains poorly understood. This study aimed to perform a biodistribution study to quantitatively assess this relationship.
methodsSpike protein encoding mRNA was encapsulated in LNPs formulated with ALC-0315. mRNA-LNP was administered intravenously in mice. Biodistribution of ALC-0315, mRNA and expressed spike protein was determined in plasma and several tissues using LC-MS/MS, RT-qPCR and ELISA, respectively. Anti-spike protein IgM and IgG titers were also quantified using ELISA.
resultsALC-0315 lipid was cleared rapidly from plasma but persists in tissue for several weeks post dosing, with highest uptake seen in liver and spleen, and the lowest in muscle and brain. Unlike lipid, the highest mRNA exposure was observed in spleen followed by liver. Spike protein expression was detected within minutes of dosing and peaked at 6 h. Maximum protein expression was observed in liver, followed by spleen, heart, kidney and lung. A robust humoral immune response was triggered against spike protein, with IgM titers detected as early as 24 h and IgG titers detected on day 7.
conclusionThe PK of lipid, mRNA, and protein components differ significantly. The plasma PK for all three analytes differed significantly from tissue PK. Synthetic ionizable lipid ALC-0315 persisted in tissues for several weeks post dosing. After intravenous dosing, mRNA-LNP was found to be rapidly taken up by the tissues, and protein expression detected within one hour in all tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.